Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Ping Zhou, MM
CONTACT
YIXUAN YANG, MD
CONTACT
Lead
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
With
IMM2520 is administered via intravenous infusion once week of cycle 1- 12 (4 weeks per cycle). The accelerated titration method and the traditional "3+3" method will be adopted to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) in dose-escalation phase. Once the RP2D is determined, Simon's two-stage design will be used to explore for each specific tumor cohort.adenocarcinoma/esophageal cancer, urothelial cancer, and/or others.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted